You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,073,945


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,073,945
Title:Alpha-IIb-beta-3 inhibitors and uses thereof
Abstract: The present invention relates to methods for the treatment or prophylaxis of thrombotic disorders comprising administration of alpha-IIB-beta-3 inhibitor compounds and compositions containing the compounds. The methods of the invention are useful for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
Inventor(s): Blue; Robert (New York, NY), Coller; Barry S. (New York, NY)
Assignee: THE ROCKEFELLER UNIVERSITY (New York, NY)
Application Number:13/441,412
Patent Claims:1. A method for inhibiting or reducing platelet aggregation and/or adhesion comprising administering to a subject in need thereof an effective amount of a compound of formula I-C: ##STR00010## wherein: i) A is S, N, C or O; ii) X is a single bond-or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4alkylene, C.sub.3-C.sub.10cycloalkylene optionally containing one or more heteroatoms selected from a group consisting of O or N, --N(R.sub.6)-- or --C.sub.1-C.sub.4alkyl-N(R.sub.6)--; iii) Y is a single bond or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4 alkylene, optionally substituted -aryl-, -arylalkylene-, -heteroaryl-, --C(O)--, --N(R.sub.6)C(O)--, --R.sub.3C(O)--, --R.sub.3-alkylamido- or --R.sub.3--NHC(O)--; iv) R.sub.1 is C.sub.1-C.sub.4alkyl; v) R.sub.3 is H or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4alkyl, optionally substituted (R.sub.6)N--, --(R.sub.4)(R.sub.5)N--, --N(R.sub.4)(R.sub.5)--C.sub.1-C.sub.4alkyl-, aryl, heteroaryl, arylC.sub.1-C.sub.4alkyl, heteroarylC.sub.1-C.sub.4alkyl, or C.sub.3-C.sub.8cycloalkyl optionally containing one or more heteroatoms selected from a group consisting of O or N; vi) R.sub.4 and R.sub.5 are linked together via a covalent bond so as to form a C.sub.3-C.sub.8cycloalkylene containing a nitrogen atom; vii) R.sub.6 is H, C.sub.1-C.sub.4alkyl, aryl or arylC.sub.1-C.sub.4alkyl, in free or pharmaceutically acceptable salt form; such that platelet aggregation and/or adhesion is reduced.

2. A method for the treatment or prophylaxis of a thrombotic disorder selected from a group consisting of stroke, myocardial infarction, unstable angina, abrupt closure following angioplasty or stent placement, thrombosis induced by peripheral vascular surgery, peripheral vascular disease and thrombotic disorders resulting from atrial fibrillation or inflammation, comprising administering to a subject in need thereof an effective amount of a Compound of Formula I-C: ##STR00011## wherein: i) A is S, N, C or O; ii) X is a single bond or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4 alkylene, C.sub.3-C.sub.10cycloalkylene optionally containing one or more heteroatoms selected from a group consisting of O or N, --N(R.sub.6)-- or --C.sub.1-C.sub.4alkyl-N(R.sub.6)--; iii) Y is a single bond or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4alkylene, optionally substituted -aryl-, -arylalkylene-, -heteroaryl-, --C(O)--, --N(R.sub.6)C(O)--, --R.sub.3C(O)--, --R.sub.3-alkylamido- or --R.sub.3--NHC(O)--; iv) R.sub.1 is C.sub.1-C.sub.4alkyl; v) R.sub.3 is H or optionally substituted and saturated or unsaturated C.sub.1-C.sub.4alkyl, optionally substituted (R.sub.6)N--, --(R.sub.4)(R.sub.5)N--, --N(R.sub.4)(R.sub.5)--C.sub.1-C.sub.4alkyl-, aryl, heteroaryl, arylC.sub.1-C.sub.4alkyl, heteroarylC.sub.1-C.sub.4alkyl, or C.sub.3-C.sub.8cycloalkyl optionally containing one or more heteroatoms selected from a group consisting of O or N; vi) R.sub.4 and R.sub.5 are linked together via a covalent bond so as to form a C.sub.3-C.sub.8cycloalkylene containing a nitrogen atom; vii) R.sub.6 is H, C.sub.1-C.sub.4alkyl, aryl or arylC.sub.1-C.sub.4alkyl, in free or pharmaceutically acceptable salt form.

3. The method according to claim 1, wherein said Compound is 2-ethyl-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one in free or pharmaceutically acceptable salt form.

4. The method according to claim 2, further comprises administering an effective amount of at least one therapeutic agent selected from a group consisting of anti-coagulant, antiplatelet, and fibrinolytic agents in conjunction with the compound as described in claim 2.

5. The method according to claim 4, wherein said therapeutic agent is selected from a group consisting of heparin, low molecular weight heparins, bivalirudin, Fondaparinux, warfarin, Acenocoumarol, Phenprocoumon, Phenindione, Abbokinase (urokinase), streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide and tirofiban.

6. The method according to claim 5 wherein said therapeutic agent is heparin.

7. The method according to claim 2, wherein said Compound is 2-ethyl-7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one in free or salt form.

8. The method according to claim 2, wherein R.sub.3 is selected from a group consisting of cyclopentyl, cyclohexyl, piperazinyl, methylpiperazinyl, ethylpiperazinyl, propylpiperazinyl, piperidinyl, azepanyl, pyrrolidinyl, imidazolidinyl, methylpyrrolidinyl, ethylpyrrolidinyl, morpholinyl and tetrahydroquinolinyl, in free or pharmaceutically acceptable salt form.

9. The method according to claim 2, wherein R.sub.4 and R.sub.5 are linked together via a covalent bond so as to form a piperidinylene, in free or pharmaceutically acceptable salt form.

10. The method according to claim 2, wherein A is S; X is a single bond; and Y is a single bond; in free or pharmaceutically acceptable salt form.

11. The method according to claim 7, further comprises administering an effective amount of at least one therapeutic agent selected from a group consisting of anti-coagulant, antiplatelet, and fibrinolytic agents in conjunction with the compound as described in claim 7.

12. The method according to claim 7, further comprises administering an effective amount of at least one therapeutic agent selected from a group consisting of heparin, low molecular weight heparins, bivalirudin, fondaparinux, warfarin, acenocoumarol, phenprocoumon, phenindione, urokinase, streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide and tirofiban.

13. The method according to claim 11 wherein said therapeutic agent is heparin.

14. The method according to claim 10, further comprises administering an effective amount of at least one therapeutic agent selected from a group consisting of anti-coagulant, antiplatelet, and fibrinolytic agents in conjunction with the compound as described in claim 10.

15. The method according to claim 10, further comprises administering an effective amount of at least one therapeutic agent selected from a group consisting of heparin, low molecular weight heparins, bivalirudin, fondaparinux, warfarin, acenocoumarol, phenprocoumon, phenindione, urokinase, streptokinase, alteplase, retaplase, tenecteplase, prasugrel, aspirin, ticlopidine, clopidogrel, abciximab, eptifibatide and tirofiban.

16. The method according to claim 15, wherein said therapeutic agent is heparin

17. the method according to claim 1, wherein A is S; X is a single bond; and Y is a single bond; in free or pharmaceutically acceptable salt form.

Details for Patent 9,073,945

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 ⤷  Try a Trial 2026-11-08
Genentech, Inc. ACTIVASE alteplase For Injection 103172 11/13/1987 ⤷  Try a Trial 2026-11-08
Genentech, Inc. CATHFLO ACTIVASE alteplase For Injection 103172 09/04/2001 ⤷  Try a Trial 2026-11-08
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 12/22/1994 ⤷  Try a Trial 2026-11-08
Genentech, Inc. TNKASE tenecteplase For Injection 103909 06/02/2000 ⤷  Try a Trial 2026-11-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.